Morphotek
- Net Worth
- $325M
- Based in
- United States
Morphotek: Biopharmaceutical monoclonal antibody developer and Eisai subsidiary, based in Exton, United States. ApexHierarchy ranks it Low State tier. Connected to 1 researched profile, including Eisai.
Biopharmaceutical monoclonal antibody developer and Eisai subsidiary
Exton, Pennsylvania, United States
Sources: 5 · Last Updated: Nov 15, 2026
As of November 2026, Morphotek's value is an estimated $325M, based on 5 cited sources. Sources
At a glance
- Reach
- 100.0K people
- Profile shape
- Even across all dimensions
- Every dimension sits at National tier
About
Morphotek, Inc. is a biopharmaceutical company founded in 2000 in Exton, Pennsylvania, based on research by Dr. Nicholas Nicolaides alongside co-founders Dr. Philip Sass and Dr. Luigi Grasso. The company developed proprietary gene evolution and antibody platforms, including Human MORPHODOMA and Libradoma, to advance targeted biological therapeutics such as farletuzumab for cancer and inflammatory conditions. In April 2007, Morphotek was acquired by Japanese pharmaceutical firm Eisai Co., Ltd. for $325 million to serve as its core biologics research unit.
How to read this profile
- The badge is the profile's overall place on a six-tier scale, from Town (local) up to Global (worldwide).
- Low, Mid, High, Top shows where it sits inside its tier compared with its peers.
- Six dimensions — net worth, reach, power, influence, network and legacy — each get their own tier. The overall tier blends them.
- ▲ ▼ ▬ show whether a dimension rose, fell or held since the last refresh.
- Sources are labelled by kind (official record, filing, business press, reference, news or web). Everything here is an editorial estimate, not a verified fact.
- Net Worth
- $325M
- Reach
- 100.0K people
- Power
- Morphotek controlled proprietary human monoclonal antibody discovery platforms and operated an $80 million pilot manufacturing plant in Exton, Pennsylvania.
- Influence
- The company advanced clinical-stage oncology drug candidates such as farletuzumab and expanded Eisai's entry into biological therapeutics.
- Network
- Morphotek maintained extensive biopharmaceutical research partnerships, including collaborations with Johns Hopkins, Abgenix, and Fujirebio Diagnostics.
- Legacy
- Morphotek pioneered morphogenic cell-line evolution technologies and served as the foundational biologics drug-creation platform for Eisai Inc.
- Trajectory ▲
- Rising ↑ — first assessment on record.
See how Morphotek's power has changed over time
Free for members. No payment, just sign in.
Sign in free to see itMore companies from the United States
Most powerful people in the United States →Richest people in the United States →
Questions about Morphotek
What is Morphotek's net worth?
Morphotek's estimated net worth is $325M as of November 2026, according to ApexHierarchy's sourced estimate.
What is Morphotek?
Morphotek, Inc. is a biopharmaceutical company founded in 2000 in Exton, Pennsylvania, based on research by Dr. Nicholas Nicolaides alongside co-founders Dr. Philip Sass and Dr. Luigi Grasso.
How powerful is Morphotek?
Morphotek is ranked Low State tier by ApexHierarchy. State-level power and recognition.
What is Morphotek known for?
Developing novel therapeutic monoclonal antibodies and proprietary gene evolution platforms prior to its $325M acquisition by Eisai.
Are these figures verified facts?
No. They are editorial estimates from public sources, shown with their sources and a confidence score on the page.
Similar Profiles
Compare Morphotek with another profile →
Known For
Developing novel therapeutic monoclonal antibodies and proprietary gene evolution platforms prior to its $325M acquisition by Eisai.
Latest news
- Morphotek Inc Lobbying Profile, 2010
OpenSecrets · 6 days ago
Headlines via Google News, linking to the original publishers.
Connections
Corporate Group (1)
Also connected to (3)
Not ranked on ApexHierarchy yet.
Sources
- Mtec-scNews or web
- EisaiNews or web
- FlagshippioneeringNews or web
- FiercebiotechNews or web
- Pharmaceutical-technologyNews or web
Cite this ranking
ApexHierarchy, “Morphotek — State tier,” November 2026. https://apexhierarchy.com/profile/morphotek
Free to quote with a link back. Every position links to its sources.